BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16996162)

  • 21. CpG oligodeoxynucleotides protect mice from lethal challenge with Candida albicans via a pathway involving tumor necrosis factor-alpha-dependent interleukin-12 induction.
    Choi JH; Ko HM; Park SJ; Kim KJ; Kim SH; Im SY
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):155-62. PubMed ID: 17854477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
    Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
    J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes.
    Yasuda K; Ogawa Y; Kishimoto M; Takagi T; Hashida M; Takakura Y
    Biochem Biophys Res Commun; 2002 Apr; 293(1):344-8. PubMed ID: 12054606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration.
    Kim DH; Moon C; Oh SS; Park S; Jeong JW; Kim S; Lee HG; Kwon HJ; Kim KD
    Nucleic Acid Ther; 2015 Apr; 25(2):95-102. PubMed ID: 25692533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
    Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
    Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular uptake and activation characteristics of naked plasmid DNA and its cationic liposome complex in human macrophages.
    Yamane I; Nishikawa M; Takakura Y
    Int J Pharm; 2005 Nov; 305(1-2):145-53. PubMed ID: 16219432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
    Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
    Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-gamma mediates suppression of erythropoiesis but not reduced red cell survival following CpG-ODN administration in vivo.
    Thawani N; Tam M; Chang KH; Stevenson MM
    Exp Hematol; 2006 Nov; 34(11):1451-61. PubMed ID: 17046564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligodeoxynucleotides containing CpG motifs (CpG-ODN) predominantly induce Th1-type immune response in neonatal chicks.
    Patel BA; Gomis S; Dar A; Willson PJ; Babiuk LA; Potter A; Mutwiri G; Tikoo SK
    Dev Comp Immunol; 2008; 32(9):1041-9. PubMed ID: 18395255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
    Inoue J; Aramaki Y
    Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Enhancement of HSP-MUC1 antitumor activity by type C CpG-ODN BW005].
    Wang XJ; Wang ZB; Wei HF; Wu XL; Wang L; Yu YL; Wang LY
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):338-40. PubMed ID: 17428390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route.
    Hattori Y; Kawakami S; Nakamura K; Yamashita F; Hashida M
    J Pharmacol Exp Ther; 2006 Aug; 318(2):828-34. PubMed ID: 16670348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA.
    Kim D; Rhee JW; Kwon S; Sohn WJ; Lee Y; Kim DW; Kim DS; Kwon HJ
    Biochem Biophys Res Commun; 2009 Feb; 379(2):362-7. PubMed ID: 19103173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells.
    Hyoudou K; Nishikawa M; Ikemura M; Kobayashi Y; Mendelsohn A; Miyazaki N; Tabata Y; Yamashita F; Hashida M
    J Control Release; 2007 Sep; 122(2):151-8. PubMed ID: 17651858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway.
    Xu W; Tamura T; Takatsu K
    Int Immunopharmacol; 2008 Feb; 8(2):351-61. PubMed ID: 18182251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity.
    Liu Y; Jiao F; Qiu Y; Li W; Lao F; Zhou G; Sun B; Xing G; Dong J; Zhao Y; Chai Z; Chen C
    Biomaterials; 2009 Aug; 30(23-24):3934-45. PubMed ID: 19403166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.
    Nikoofal-Sahlabadi S; Matbou Riahi M; Sadri K; Badiee A; Nikpoor AR; Jaafari MR
    Eur J Pharm Sci; 2018 Jul; 119():159-170. PubMed ID: 29660463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal administration of pMP6/liposome complexes inhibits the growth of co-localized colon-26 adenocarcinoma cells by inducing a tumor-specific immune response.
    Sturlan S; Schneeberger A; Fang M; Beinhauer BG; Lührs P; Kutil R; Wessner B; Huang L; Aasen AO; Rogy MA
    Anticancer Res; 2003; 23(6C):4843-51. PubMed ID: 14981934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.